Novel vaccine development strategies for inducing mucosal immunity

References

• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25(30), 5467–5484 (2007).
   Google Scholar
• Lamm ME. Current concepts in mucosal immunity IV. How epithelial transport of IgA antibodies relates to host defense. Am. J. Physiol. 274(4 Pt 1), G614–G617 (1998).
   PubMed Web of Science ®Google Scholar
• Russell MW, Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 4(6), 667–677 (2002).
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Boyaka PN, McGhee JR. Host defenses at mucosal surfaces. In: Clinical Immunology. Rich RT et al. (Eds). Mosby Elsevier, PA, USA, 287–304 (2008).
   Google Scholar
• Kiyono H, Kunisawa J, McGhee JR, Mestecky J. The mucosal imune system. In: Fundamental Immunology. Paul WE (Ed.). Lippincott Williams & Wilkins, PA, USA, 983–1030 (2008).
   Google Scholar
• Hamada H, Hiroi T, Nishiyama Y et al. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J. Immunol. 168(1), 57–64 (2002).
   PubMed Web of Science ®Google Scholar
• Lorenz RG, Chaplin DD, McDonald KG, McDonough JS, Newberry RD. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J. Immunol. 170(11), 5475–5482 (2003).
   PubMed Web of Science ®Google Scholar
• Nagatake T, Fukuyama S, Kim DY et al. Id2-, RORγt-, and LTβR-independent initiation of lymphoid organogenesis in ocular immunity. J. Exp. Med. 206(11), 2351–2364 (2009).
   PubMed Web of Science ®Google Scholar
• Seo KY, Han SJ, Cha HR et al. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J. Immunol. 185(6), 3610–3619 (2010).
   PubMed Web of Science ®Google Scholar
• Lamm ME, Phillips-Quagliata JM. Origin and homing of intestinal IgA antibody-secreting cells. J. Exp. Med. 195(2), F5–F8 (2002).
   PubMed Web of Science ®Google Scholar
• Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol. 1(1), 11–22 (2008).
   PubMed Web of Science ®Google Scholar
• Mestecky J, Lue C, Russell MW. Selective transport of IgA. Cellular and molecular aspects. Gastroenterol. Clin. North Am. 20(3), 441–471 (1991).
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4+ T cells activated in cutaneous or mucosal lymphoid tissues. J. Exp. Med. 195(1), 135–141 (2002).
   PubMed Web of Science ®Google Scholar
• Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. Role of α4-integrins in lymphocyte homing to mucosal tissues in vivo. J. Immunol. 152(7), 3282–3293 (1994).
   PubMed Web of Science ®Google Scholar
• Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J. Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J. Immunol. 162(9), 5173–5177 (1999).
   PubMed Web of Science ®Google Scholar
• Svensson M, Marsal J, Ericsson A et al. CCL25 mediates the localization of recently activated CD8αβ+ lymphocytes to the small-intestinal mucosa. J. Clin. Invest. 110(8), 1113–1121 (2002).
   PubMed Web of Science ®Google Scholar
• Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv. Immunol. 72, 209–253 (1999).
   PubMed Web of Science ®Google Scholar
• Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21(4), 527–538 (2004).
   PubMed Web of Science ®Google Scholar
• McGhee JR, Kunisawa J, Kiyono H. Gut lymphocyte migration, we are halfway ‘home’. Trends Immunol. 28(4), 150–153 (2007).
   PubMed Web of Science ®Google Scholar
• Mora JR, Iwata M, Eksteen B et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 314(5802), 1157–1160 (2006).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(Suppl. 4), S45–S53 (2005).
   PubMed Web of Science ®Google Scholar
• Kantele A, Hakkinen M, Moldoveanu Z et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect. Immun. 66(12), 5630–5635 (1998).
   PubMed Web of Science ®Google Scholar
• Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 16(2), 187–201 (1997).
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Brightling CE, Symon FA et al. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J. Immunol. 166(4), 2842–2848 (2001).
   PubMed Web of Science ®Google Scholar
• Csencsits KL, Walters N, Pascual DW. Cutting edge: dichotomy of homing receptor dependence by mucosal effector B cells: α(E) versus L-selectin. J. Immunol. 167(5), 2441–2445 (2001).
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol. 30(7), 334–343 (2009).
   PubMed Web of Science ®Google Scholar
• Fujihashi K, McGhee JR. Mucosal immunity and tolerance in the elderly. Mech. Ageing Dev. 125(12), 889–898 (2004).
   PubMedGoogle Scholar
• Fukuyama,S, Hiroi T, Yokota Y et al. Initiation of NALT organogenesis is independent of the IL-7R, LTβR, and NIK signaling pathways but requires the Id2 gene and CD3- CD4+CD45+ cells. Immunity 17(1), 31–40 (2002).
   PubMed Web of Science ®Google Scholar
• Hagiwara Y, McGhee JR, Fujihashi K et al. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. J. Immunol. 170(4), 1754–1762 (2003).
   PubMedGoogle Scholar
• Kato H, Fujihashi K, Kato R et al. Lack of oral tolerance in aging is due to sequential loss of Peyer's patch cell interactions. Int. Immunol. 15(2), 145–158 (2003).
   PubMedGoogle Scholar
• Koga T, McGhee JR, Kato H, Kato R, Kiyono H, Fujihashi K. Evidence for early aging in the mucosal immune system. J. Immunol. 165, 5352–5359 (2000).
   PubMedGoogle Scholar
• Kunisawa J, Nochi T, Kiyono H. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol. 29(11), 505–513 (2008).
   PubMed Web of Science ®Google Scholar
• Pascual DW, Riccardi C, Csencsits-Smith K. Distal IgA immunity can be sustained by αEβ7+ B cells in L-selectin-/- mice following oral immunization. Mucosal Immunol. 1(1), 68–77 (2008).
   PubMedGoogle Scholar
• Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS. Surface lymphotoxin α/β complex is required for the development of peripheral lymphoid organs. J. Exp. Med. 184(5), 1999–2006 (1996).
   PubMed Web of Science ®Google Scholar
• Yoshida H, Honda K, Shinkura R et al. IL-7 receptor α+ CD3(-) cells in the embryonic intestine induces the organizing center of Peyer's patches. Int. Immunol. 11(5), 643–655 (1999).
   PubMedGoogle Scholar
• Kurebayashi S, Ueda E, Sakaue M et al. Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc. Natl Acad. Sci. USA 97(18), 10132–10137 (2000).
   PubMed Web of Science ®Google Scholar
• Sun Z, Unutmaz D, Zou YR et al. Requirement for RORγ in thymocyte survival and lymphoid organ development. Science 288(5475), 2369–2373 (2000).
   PubMed Web of Science ®Google Scholar
• Yokota Y, Mansouri A, Mori S et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397(6721), 702–706 (1999).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Hochrein H, Shortman K, Vremec D, Scott B, Hertzog P, O'Keeffe M. Differential production of IL-12, IFN-α, and IFN-γ by mouse dendritic cell subsets. J. Immunol. 166(9), 5448–5455 (2001).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22(1), 41–47 (2001).
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201–216 (2004).
   PubMed Web of Science ®Google Scholar
• Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73, 329–368 (1999).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl Acad. Sci. USA 93(7), 2879–2883 (1996).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148(12), 4072–4076 (1992).
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Egeter O, Hausmann S et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160(8), 3627–3630 (1998).
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Investig. Drugs 4(6), 686–690 (2003).
   PubMedGoogle Scholar
• Kline JN, Waldschmidt TJ, Businga TR et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160(6), 2555–2559 (1998).
   PubMed Web of Science ®Google Scholar
• Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA 95(26), 15553–15558 (1998).
   PubMed Web of Science ®Google Scholar
• Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160(2), 870–876 (1998).
   PubMed Web of Science ®Google Scholar
• Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19(13–14), 1636–1642 (2001).
   Google Scholar
• Klinman DM. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 8(2), 181–184 (1998).
   PubMedGoogle Scholar
• Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 17(1), 19–25 (1999).
   PubMed Web of Science ®Google Scholar
• Kovarik J, Bozzotti P, Love-Homan L et al. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162(3), 1611–1617 (1999).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161(9), 4463–4466 (1998).
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16(11–12), 1216–1224 (1998).
   Google Scholar
• McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19(7–8), 950–957 (2000).
   Google Scholar
• Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol. Med. Microbiol. 32(1), 65–71 (2001).
   PubMedGoogle Scholar
• Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J. Immunol. 168(9), 4711–4720 (2002).
   PubMed Web of Science ®Google Scholar
• Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170(11), 5636–5643 (2003).
   PubMed Web of Science ®Google Scholar
• Brasel K, McKenna HJ, Morrissey PJ et al. Hematologic effects of flt3 ligand in vivo in mice. Blood 88, 2004–2012 (1996).
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Brasel K, Teepe M et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953–1962 (1996).
   PubMed Web of Science ®Google Scholar
• Lyman SD, James L, Johnson L et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 83(10), 2795–2801 (1994).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Banchereau J, Burkeholder S et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165(1), 566–572 (2000).
   PubMed Web of Science ®Google Scholar
• Robinson S, Mosley RL, Parajuli P et al. Comparison of the hematopoietic activity of flt-3 ligand and granulocyte-macrophage colony-stimulating factor acting alone or in combination. J. Hematother. Stem Cell Res. 9(5), 711–720 (2000).
   PubMedGoogle Scholar
• Small D, Levenstein M, Kim E et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl Acad. Sci. USA 91(2), 459–463 (1994).
   PubMed Web of Science ®Google Scholar
• Lyman SD, James L, Vanden Bos T et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75(6), 1157–1167 (1993).
   PubMed Web of Science ®Google Scholar
• Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J. Immunol. 160, 5815–5825 (1998).
   PubMed Web of Science ®Google Scholar
• Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 163, 3668–3675 (1999).
   PubMed Web of Science ®Google Scholar
• Pisarev VM, Parajuli P, Mosley RL et al. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. Int. J. Immunopharmacol. 22(11), 865–876 (2000).
   PubMedGoogle Scholar
• Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology 107, 69–76 (2002).
   PubMedGoogle Scholar
• Hung CF, Hsu KF, Cheng WF et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 61, 1080–1088 (2001).
   PubMed Web of Science ®Google Scholar
• Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76, 243–250 (2002).
   PubMed Web of Science ®Google Scholar
• Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58(3), 380–383 (1998).
   PubMed Web of Science ®Google Scholar
• Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3(6), 625–631 (1997).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Smith JL, Caspary G et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA 96(3), 1036–1041 (1999).
   PubMed Web of Science ®Google Scholar
• Vollstedt S, Franchini M, Hefti HP et al. Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J. Exp. Med. 197(5), 575–584 (2003).
   PubMedGoogle Scholar
• Kataoka K, McGhee JR, Kobayashi R, Fujihashi K, Shizukuishi S, Fujihashi K. Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity. J. Immunol. 172(6), 3612–3619 (2004).
   PubMed Web of Science ®Google Scholar
• Sekine S, Kataoka K, Fukuyama Y et al. A novel adenovirus expressing flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J. Immunol. 180(12), 8126–8134 (2008).
   PubMedGoogle Scholar
• Fukuiwa T, Sekine S, Kobayashi R et al. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 26(37), 4849–4859 (2008).
   PubMed Web of Science ®Google Scholar
• Fukuyama Y, King JD, Kataoka K et al. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice. J. Immunol. 186(4), 2454–2461 (2011).
   PubMed Web of Science ®Google Scholar
• Bockman DE, Cooper MD. Pinocytosis by epithelium associated with lymphoid follicles in the bursa of Fabricius, appendix, and Peyer's patches. An electron microscopic study. Am. J. Anat. 136(4), 455–477 (1973).
   PubMedGoogle Scholar
• Farstad IN, Halstensen TS, Fausa O, Brandtzaeg P. Heterogeneity of M-cell-associated B and T cells in human Peyer's patches. Immunology 83(3), 457–464 (1994).
   PubMed Web of Science ®Google Scholar
• Gebert A, Rothkotter HJ, Pabst R. M cells in Peyer's patches of the intestine. Int. Rev. Cytol. 167, 91–159 (1996).
   PubMed Web of Science ®Google Scholar
• Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells, gateways for mucosal infection and immunization. Cell 86(3), 345–348 (1996).
   PubMed Web of Science ®Google Scholar
• Owen RL, Jones AL. Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 66(2), 189–203 (1974).
   PubMed Web of Science ®Google Scholar
• Wolf JL, Bye WA. The membranous epithelial (M) cell and the mucosal immune system. Annu. Rev. Med. 35, 95–112 (1984).
   PubMed Web of Science ®Google Scholar
• Ermak TH, Dougherty EP, Bhagat HR, Kabok Z, Pappo J. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells. Cell Tissue Res. 279(2), 433–436 (1995).
   PubMed Web of Science ®Google Scholar
• Allan CH, Mendrick DL, Trier JS. Rat intestinal M cells contain acidic endosomal-lysosomal compartments and express class II major histocompatibility complex determinants. Gastroenterology 104(3), 698–708 (1993).
   PubMed Web of Science ®Google Scholar
• Jones BD, Ghori N, Falkow S. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J. Exp. Med. 180(1), 15–23 (1994).
   PubMed Web of Science ®Google Scholar
• Teitelbaum R, Schubert W, Gunther L et al. The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis. Immunity 10(6), 641–650 (1999).
   PubMed Web of Science ®Google Scholar
• Jang, MH, Kweon MN, Iwatani K et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc. Natl Acad. Sci. USA 101(16), 6110–6115 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Rennert P, McGhee JR et al. Alternate mucosal immune system: organized Peyer's patches are not required for IgA responses in the gastrointestinal tract. J. Immunol. 164(10), 5184–5189 (2000).
   PubMed Web of Science ®Google Scholar
• Wolf JL, Rubin DH, Finberg R et al. Intestinal M cells: a pathway for entry of reovirus into the host. Science 212(4493), 471–472 (1981).
   PubMed Web of Science ®Google Scholar
• Nibert ML, Furlong DB, Fields BN. Mechanisms of viral pathogenesis. Distinct forms of reoviruses and their roles during replication in cells and host. J. Clin. Invest. 88(3), 727–734 (1991).
   PubMedGoogle Scholar
• Wu Y, Boysun MJ, Csencsits KL, Pascual DW. Gene transfer facilitated by a cellular targeting molecule, reovirus protein σ1. Gene Ther. 7(1), 61–69 (2000).
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. M cell-targeted DNA vaccination. Proc. Natl Acad. Sci. USA 98(16), 9318–9323 (2001).
   PubMed Web of Science ®Google Scholar
• Nochi T, Yuki Y, Matsumura A et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J. Exp. Med. 204(12), 2789–2796 (2007).
   PubMed Web of Science ®Google Scholar
• Kim SH, Seo KW, Kim J, Lee KY, Jang YS. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J. Immunol. 185(10), 5787–5795 (2010).
   PubMed Web of Science ®Google Scholar
• Rynda A, Maddaloni M, Mierzejewska D et al. Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein σ1. J. Immunol. 180(8), 5187–5200 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Sekine S, Kataoka K et al. Ovalbumin-protein σ1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology 135(3), 917–925 (2008).
   PubMed Web of Science ®Google Scholar
• Arakawa T, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 16(3), 292–297 (1998).
   PubMed Web of Science ®Google Scholar
• Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268, 714–716 (1995).
   PubMed Web of Science ®Google Scholar
• Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl Acad. Sci. USA 93(11), 5335–5340 (1996).
   PubMed Web of Science ®Google Scholar
• Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 16(13), 1336–1343 (1998).
   PubMed Web of Science ®Google Scholar
• Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol. 18(11), 1167–1171 (2000).
   PubMed Web of Science ®Google Scholar
• Sandhu JS, Krasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE. Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. Transgenic Res. 9(2), 127–135 (2000).
   PubMed Web of Science ®Google Scholar
• Streatfield SJ, Jilka JM, Hood EE et al. Plant-based vaccines: unique advantages. Vaccine 19(17–19), 2742–2748 (2001).
   Google Scholar
• Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. 4(5), 607–609 (1998).
   PubMed Web of Science ®Google Scholar
• Nochi T, Takagi H, Yuki Y et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl Acad. Sci. USA 104(26), 10986–10991 (2007).
   PubMed Web of Science ®Google Scholar
• Tokuhara D, Yuki Y, Nochi T et al. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc. Natl Acad. Sci. USA 107(19), 8794–8799 (2010).
   PubMed Web of Science ®Google Scholar
• Nochi T, Yuki Y, Katakai Y et al. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. J. Immunol. 183(10), 6538–6544 (2009).
   PubMedGoogle Scholar
• Yuki Y, Tokuhara D, Nochi T et al. Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine 27(43), 5982–5988 (2009).
   PubMedGoogle Scholar
• de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenburg GJ, Palache AM, Wilschut J. Mucosal immunoadjuvant activity of liposomes, induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13(2), 155–162 (1995).
   PubMedGoogle Scholar
• de Haan A, Tomee JF, Huchshorn JP, Wilschut J. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 13(14), 1320–1324 (1995).
   PubMedGoogle Scholar
• Ernst WA, Kim HJ, Tumpey TM et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24(24), 5158–5168 (2006).
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Ichinohe T, Strong P et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J. Med. Virol. 75(1), 130–136 (2005).
   PubMed Web of Science ®Google Scholar
• Marinaro M, Boyaka PN, Finkelman FD et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185(3), 415–427 (1997).
   PubMed Web of Science ®Google Scholar
• Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials, developing the next generation of vaccines. Trends Immunol. 27(12), 573–579 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma S, Mukkur TK, Benson HA, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 98(3), 812–843 (2009).
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Gluck R. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17(11–12), 1301–1305 (1999).
   Google Scholar
• Alving CR. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta 1113(3–4), 307–322 (1992).
   Google Scholar
• Brochu H, Polidori A, Pucci B, Vermette P. Drug delivery systems using immobilized intact liposomes: a comparative and critical review. Curr. Drug Deliv. 1(3), 299–312 (2004).
   PubMedGoogle Scholar
• Gregoriadis, G. Immunological adjuvants: a role for liposomes. Immunol. Today 11(3), 89–97 (1990).
   PubMedGoogle Scholar
• Amidi M, Romeijn SG, Verhoef JC et al. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25(1), 144–153 (2007).
   PubMed Web of Science ®Google Scholar
• Gilmore JL, Yi X, Quan L, Kabanov AV. Novel nanomaterials for clinical neuroscience. J. Neuroimmune Pharmacol. 3(2), 83–94 (2008).
   PubMed Web of Science ®Google Scholar
• Kageyama S, Kitano S, Hirayama M et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci. 99(3), 601–607 (2008).
   PubMed Web of Science ®Google Scholar
• Nomura Y, Ikeda M, Yamaguchi N, Aoyama Y, Akiyoshi K. Protein refolding assisted by self-assembled nanogels as novel artificial molecular chaperone. FEBS Lett. 553(3), 271–276 (2003).
   PubMed Web of Science ®Google Scholar
• Nochi T, Yuki Y, Takahashi H et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9(7), 572–578 (2010).
   PubMed Web of Science ®Google Scholar
• Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 21 (Suppl. 2), S68–S76 (2003).
   Google Scholar
• Lehner T, Wang Y, Whittall T, Seidl T. Innate immunity and HIV-1 infection. Adv. Dent. Res. 23(1), 19–22 (2011).
   PubMedGoogle Scholar
• Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80(11), 5283–5291 (2006).
   PubMed Web of Science ®Google Scholar
• Tengvall S, O'Hagan D, Harandi AM. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Antiviral Res. 78(3), 202–214 (2008).
   PubMedGoogle Scholar
• Mowat AM, Faria AM, Weiner HL. Oral tolerance: physiological basis and clinical applications. In: Mucosal Immunology. Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L (Eds.). Elsevier/Academic Press, CA, USA, 487–537 (2004).
   Google Scholar
• Frati F, Moingeon P, Marcucci F et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc. 28(1), 35–39 (2007).
   PubMed Web of Science ®Google Scholar
• Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61(2), 151–165 (2006).
   PubMed Web of Science ®Google Scholar
• Sun JB, Czerkinsky C, Holmgren J. Sublingual ‘oral tolerance’ induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. Scand. J. Immunol. 66(2–3), 278–286 (2007).
   Google Scholar
• Sun JB, Raghavan S, Sjoling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells. J. Immunol. 177(11), 7634–7644 (2006).
   PubMed Web of Science ®Google Scholar
• Hagiwara Y, Kawamura YI, Kataoka K et al. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J. Immunol. 177(5), 3045–3054 (2006).
   PubMedGoogle Scholar
• van Ginkel FW, Jackson RJ, Yoshino N et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect. Immun. 73(10), 6892–6902 (2005).
   PubMedGoogle Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165(9), 4778–4782 (2000).
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, McGhee JR, Watt JM, Campos-Torres A, Parish LA, Briles DE. Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc. Natl Acad. Sci. USA 100(24), 14363–14367 (2003).
   PubMedGoogle Scholar
• Yoshino N, Lu FX, Fujihashi K et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J. Immunol. 173(11), 6850–6857 (2004).
   PubMed Web of Science ®Google Scholar
• BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32(8), 2274–2281 (2002).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Brazolot Millan CL, Gramzinski RA et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5(5), 287–300 (1999).
   PubMed Web of Science ®Google Scholar
• Montgomery PC, Rafferty DE. Induction of secretory and serum antibody responses following oral administration of antigen with bioadhesive degradable starch microparticles. Oral Microbiol. Immunol. 13(3), 139–149 (1998).
   PubMedGoogle Scholar
• Song, JH, Kim JI, Kwon HJ et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J. Immunol. 182(11), 6851–6860 (2009).
   PubMed Web of Science ®Google Scholar
• Song JH, Nguyen HH, Cuburu N et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 105(5), 1644–1649 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang T, Hashizume T, Kurita-Ochiai T, Yamamoto M. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem. Biophys. Res. Commun. 390(3), 937–941 (2009).
   PubMed Web of Science ®Google Scholar
• Knop E, Knop N. Lacrimal drainage-associated lymphoid tissue (LDALT): a part of the human mucosal immune system. Invest. Ophthalmol. Vis. Sci. 42(3), 566–574 (2001).
   PubMed Web of Science ®Google Scholar
• Knop N, Knop E. Conjunctiva-associated lymphoid tissue in the human eye. Invest. Ophthalmol. Vis. Sci. 41(6), 1270–1209 (2000).
   PubMed Web of Science ®Google Scholar
• Cain C, Phillips TE. Developmental changes in conjunctiva-associated lymphoid tissue of the rabbit. Invest. Ophthalmol. Vis. Sci. 49(2), 644–649 (2008).
   PubMed Web of Science ®Google Scholar
• Chodosh J, Nordquist RE, Kennedy RC. Comparative anatomy of mammalian conjunctival lymphoid tissue: a putative mucosal immune site. Dev. Comp. Immunol. 22(5–6), 621–630 (1998).
   Google Scholar
• Giuliano EA, Moore CP, Phillips TE. Morphological evidence of M cells in healthy canine conjunctiva-associated lymphoid tissue. Graefes Arch. Clin. Exp. Ophthalmol. 240(3), 220–226 (2002).
   PubMedGoogle Scholar
• Gomes JA, Jindal VK, Gormley PD, Dua HS. Phenotypic analysis of resident lymphoid cells in the conjunctiva and adnexal tissues of rat. Exp. Eye Res. 64(6), 991–997 (1997).
   PubMed Web of Science ®Google Scholar
• Knop N, Knop E. Ultrastructural anatomy of CALT follicles in the rabbit reveals characteristics of M-cells, germinal centres and high endothelial venules. J. Anat. 207(4), 409–426 (2005).
   PubMed Web of Science ®Google Scholar